---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-028993"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:20:15.637426+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q4 DEXTENZA rev $13.9M (+14% YoY); guides 2023 rev $55-60M; net loss $71M

## Summary
- DEXTENZA net product revenue Q4 2022 $13.9M (+14% YoY, +17% QoQ); full year $50.5M (+20% YoY).
- Total net revenue full year 2022 $51.5M (+18% YoY); net loss $(71.0)M vs $(6.6)M in 2021 (includes $5.2M non-cash item).
- Cash and equivalents $102.3M at Dec 31, 2022; company expects cash runway to mid-2024.
- OTX-TKI Phase 1 wet AMD: 73% rescue-free at 10 months; 92% reduction in treatment burden; pivotal trial planned Q3 2023.
- OTX-TIC Phase 2 glaucoma top-line data expected Q4 2023; Phase 1 diabetic retinopathy trial initiated Dec 2022.

## SEC filing metadata
- accession: 0001104659-23-028993
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/0001104659-23-028993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/tm238596d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-028993
- JSON: https://secwatch.observer/filing/0001104659-23-028993.json
- Plain text: https://secwatch.observer/filing/0001104659-23-028993.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported the fourth quarter and year ended December 31, 2022 results: revenue $51.5 million.
  - Period: the fourth quarter and year ended December 31, 2022
  - Revenue: $51.5 million
  - Result: reported results
  source text: intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2023 Total Net Revenue for Full Year 2022 was $51.5 million, Representing Growth of 18% Over the Prior Year DEXTENZA ® Net Product Revenue in the Fourth Quarter of 2022 was $13.9 million, Representing Growth of approximately 17% Over
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/0001104659-23-028993-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.